Year None20262025202420232022202120202019201820172016 May 13, 2026 Medicenna Announces the Launch of a Marketed Public Offering of Securities Go to May 12, 2026 Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma Go to April 30, 2026 Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026 Go to April 21, 2026 Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026 Go to April 14, 2026 Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference Go to April 9, 2026 Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer Go to Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last »
May 12, 2026 Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma Go to
April 30, 2026 Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026 Go to
April 21, 2026 Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026 Go to
April 14, 2026 Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference Go to
